恩瑞格治疗铁质积聚疗效怎么样呢？

Iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, it is convenient to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment. Today we will take a look at the effectiveness of Enrige in treating iron accumulation?

Enrig dispersible tablets can effectively help treat beta-thalassemia in adults and children. The specific usage and dosage are: It is recommended for patients with iron accumulation, such as those who require long-term blood transfusion (blood transfusion volume reaches 100ml/kg) and whose serum ferritin exceeds 1000ug/liter; corresponding to the body weight, it is recommended to take 20mg/kg daily at the initial stage. Enrig, depending on the improvement of serum ferritin indicators, patients may need to adjust or increase the dose of Enrig. Generally, the dose will be increased in units of 5 mg/kg or 10 mg/kg, but the total dose should not exceed 30 mg/kg per day.

The research screened and optimized the prescription of Enrig dispersible tablets. The disintegration time limit and 30-minute cumulative dissolution were used as inspection indicators. The dosage of diluent microcrystalline cellulose (MCC) and lactose, the mass ratio of disintegrant cross-linked povidone (PVPP), and the amount of cosolvent sodium dodecyl sulfate (SDS) were used as factors. The L9 (34) orthogonal test table was used to design the test plan. The prescription of Enrig dispersible tablets was screened and the prescription was verified. The results showed that the optimized prescription was 12.5% ​​MCC, 27.5% lactose, 18% PVPP (internally added), and 1.0% SDS. In the verification test, Enrig dispersible tablets completely disintegrated within 120 s, with an average 30-minute cumulative dissolution of 86.0%, which has a greater advantage than ordinary tablets. It can be seen that the dissolution rate, disintegration time and other indicators of Enrig dispersible tablets prepared according to this prescription meet the requirements.

The therapeutic effect of Enrige dispersible tablets is worthy of recognition. Enrig dispersible tablets have three protruding ligands that bind iron with high affinity in a ratio of 2:1. Although Enriga has a very low affinity for zinc and copper, the concentrations of these trace metals in serum decreased to varying degrees after administration.

The above is the content of the effect, I hope it can help you!